Update on corticosteroids for diabetic macular edema

Stephen G Schwartz,1 Ingrid U Scott,2,3 Michael W Stewart,4 Harry W Flynn Jr1 1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, 2Department of Ophthalmology, 3Department of Public Health Sciences, Penn State College of Medicine, Her...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Schwartz SG, Scott IU, Stewart MW, Flynn HW Jr
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Diabetic macular edema (DME) Vascular endothelial growth factor (VEGF) Triamcinolone acetonide Dexamethasone Fluocinolone acetonide Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/de662269881c4c5da1c0794bf1b568c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de662269881c4c5da1c0794bf1b568c2
record_format	dspace
spelling	oai:doaj.org-article:de662269881c4c5da1c0794bf1b568c22021-12-02T00:22:17ZUpdate on corticosteroids for diabetic macular edema1177-5483https://doaj.org/article/de662269881c4c5da1c0794bf1b568c22016-09-01T00:00:00Zhttps://www.dovepress.com/update-on-corticosteroids-for-diabetic-macular-edema-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Stephen G Schwartz,1 Ingrid U Scott,2,3 Michael W Stewart,4 Harry W Flynn Jr1 1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, 2Department of Ophthalmology, 3Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, 4Department of Ophthalmology, Mayo Clinic Florida, Jacksonville, FL, USA Abstract: Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for corticosteroids as well. Corticosteroids may be especially useful in pseudophakic patients poorly responsive to anti-VEGF therapies, in patients wishing to reduce the number of required injections, and in pregnant patients. Intravitreal triamcinolone acetonide has been used for many years but is not approved for this indication. An extended-release bioerodable dexamethasone delivery system and an extended-release nonbioerodable fluocinolone acetonide insert have both achieved regulatory approval for the treatment of DME. All intravitreal corticosteroids are associated with risks of cataract progression, elevation of intraocular pressure, and endophthalmitis. There is no current consensus regarding the use of corticosteroids, but they are valuable for selected patients with center-involving DME. Keywords: diabetic macular edema, vascular endothelial growth factor, triamcinolone acetonide, dexamethasone, fluocinolone acetonide, randomized clinical trialSchwartz SGScott IUStewart MWFlynn HW JrDove Medical PressarticleDiabetic macular edema (DME)Vascular endothelial growth factor (VEGF) Triamcinolone acetonide Dexamethasone Fluocinolone acetonideOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 10, Pp 1723-1730 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diabetic macular edema (DME) Vascular endothelial growth factor (VEGF) Triamcinolone acetonide Dexamethasone Fluocinolone acetonide Ophthalmology RE1-994
spellingShingle	Diabetic macular edema (DME) Vascular endothelial growth factor (VEGF) Triamcinolone acetonide Dexamethasone Fluocinolone acetonide Ophthalmology RE1-994 Schwartz SG Scott IU Stewart MW Flynn HW Jr Update on corticosteroids for diabetic macular edema
description	Stephen G Schwartz,1 Ingrid U Scott,2,3 Michael W Stewart,4 Harry W Flynn Jr1 1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, 2Department of Ophthalmology, 3Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, 4Department of Ophthalmology, Mayo Clinic Florida, Jacksonville, FL, USA Abstract: Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for corticosteroids as well. Corticosteroids may be especially useful in pseudophakic patients poorly responsive to anti-VEGF therapies, in patients wishing to reduce the number of required injections, and in pregnant patients. Intravitreal triamcinolone acetonide has been used for many years but is not approved for this indication. An extended-release bioerodable dexamethasone delivery system and an extended-release nonbioerodable fluocinolone acetonide insert have both achieved regulatory approval for the treatment of DME. All intravitreal corticosteroids are associated with risks of cataract progression, elevation of intraocular pressure, and endophthalmitis. There is no current consensus regarding the use of corticosteroids, but they are valuable for selected patients with center-involving DME. Keywords: diabetic macular edema, vascular endothelial growth factor, triamcinolone acetonide, dexamethasone, fluocinolone acetonide, randomized clinical trial
format	article
author	Schwartz SG Scott IU Stewart MW Flynn HW Jr
author_facet	Schwartz SG Scott IU Stewart MW Flynn HW Jr
author_sort	Schwartz SG
title	Update on corticosteroids for diabetic macular edema
title_short	Update on corticosteroids for diabetic macular edema
title_full	Update on corticosteroids for diabetic macular edema
title_fullStr	Update on corticosteroids for diabetic macular edema
title_full_unstemmed	Update on corticosteroids for diabetic macular edema
title_sort	update on corticosteroids for diabetic macular edema
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/de662269881c4c5da1c0794bf1b568c2
work_keys_str_mv	AT schwartzsg updateoncorticosteroidsfordiabeticmacularedema AT scottiu updateoncorticosteroidsfordiabeticmacularedema AT stewartmw updateoncorticosteroidsfordiabeticmacularedema AT flynnhwjr updateoncorticosteroidsfordiabeticmacularedema
_version_	1718403835824701440

Update on corticosteroids for diabetic macular edema

Ejemplares similares